company background image
R2WA logo

Beximco Pharmaceuticals DB:R2WA Stock Report

Last Price

€0.47

Market Cap

€441.1m

7D

7.8%

1Y

13.5%

Updated

22 Mar, 2024

Data

Company Financials +

Beximco Pharmaceuticals Limited

DB:R2WA Stock Report

Market Cap: €441.1m

R2WA Stock Overview

Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh.

R2WA fundamental analysis
Snowflake Score
Valuation5/6
Future Growth3/6
Past Performance3/6
Financial Health6/6
Dividends5/6

Beximco Pharmaceuticals Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Beximco Pharmaceuticals
Historical stock prices
Current Share Price৳0.47
52 Week High৳0.53
52 Week Low৳0.37
Beta0.64
1 Month Change8.80%
3 Month Change7.80%
1 Year Change13.53%
3 Year Change-53.92%
5 Year Change0.19%
Change since IPO17.27%

Recent News & Updates

Recent updates

Shareholder Returns

R2WADE PharmaceuticalsDE Market
7D7.8%1.1%1.2%
1Y13.5%-23.8%5.5%

Return vs Industry: R2WA exceeded the German Pharmaceuticals industry which returned -23.8% over the past year.

Return vs Market: R2WA exceeded the German Market which returned 5.5% over the past year.

Price Volatility

Is R2WA's price volatile compared to industry and market?
R2WA volatility
R2WA Average Weekly Movement8.0%
Pharmaceuticals Industry Average Movement6.2%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.0%
10% least volatile stocks in DE Market2.5%

Stable Share Price: R2WA has not had significant price volatility in the past 3 months.

Volatility Over Time: R2WA's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
1976n/an/ahttps://www.beximcopharma.com

Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh. The company provides allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskeletal, oncology, respiratory, urogenital, skin care, vitamin and mineral supplement, and other products, as well as contract manufacturing services to other companies. It offers its products in various dosage forms, including solid, liquid, cream and ointment, suppositories, metered dose and dry powder inhaler, nasal spray, sterile, lyophilized injectable, and large volume intravenous fluids.

Beximco Pharmaceuticals Limited Fundamentals Summary

How do Beximco Pharmaceuticals's earnings and revenue compare to its market cap?
R2WA fundamental statistics
Market cap€441.08m
Earnings (TTM)€41.48m
Revenue (TTM)€351.38m

10.6x

P/E Ratio

1.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
R2WA income statement (TTM)
Revenue৳41.65b
Cost of Revenue৳23.62b
Gross Profit৳18.03b
Other Expenses৳13.12b
Earnings৳4.92b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)11.02
Gross Margin43.30%
Net Profit Margin11.80%
Debt/Equity Ratio14.5%

How did R2WA perform over the long term?

See historical performance and comparison

Dividends

3.0%

Current Dividend Yield

32%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.